| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10048938 | HBV | ENSG00000135046.15 | protein_coding | ANXA1 | No | No | 301 | P04083 Q5TZZ9 |
| TVIS10048939 | HBV | ENSG00000135046.15 | protein_coding | ANXA1 | No | No | 301 | P04083 Q5TZZ9 |
| TVIS10048510 | HBV | ENSG00000135046.15 | protein_coding | ANXA1 | No | No | 301 | P04083 Q5TZZ9 |
| TVIS10048511 | HBV | ENSG00000135046.15 | protein_coding | ANXA1 | No | No | 301 | P04083 Q5TZZ9 |
| TVIS30013712 | HIV | ENSG00000135046.15 | protein_coding | ANXA1 | No | No | 301 | P04083 Q5TZZ9 |
| TVIS30071026 | HIV | ENSG00000135046.15 | protein_coding | ANXA1 | No | No | 301 | P04083 Q5TZZ9 |
| TVIS20063381 | HPV | ENSG00000135046.15 | protein_coding | ANXA1 | No | No | 301 | P04083 Q5TZZ9 |
| TVIS20020573 | HPV | ENSG00000135046.15 | protein_coding | ANXA1 | No | No | 301 | P04083 Q5TZZ9 |
| TVIS44036230 | HTLV-1 | ENSG00000135046.15 | protein_coding | ANXA1 | No | No | 301 | P04083 Q5TZZ9 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | ANXA1 |
|---|---|
| DrugBank ID | DB00741 |
| Drug Name | Hydrocortisone |
| Target ID | BE0000422 |
| UniProt ID | P04083 |
| Regulation Type | agonist |
| PubMed IDs | 17139284; 17016423; 11142771; 1712816; 8060156 |
| Citations | Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@Sato-Matsumura KC, Matsumura T, Nakamura H, Sawa H, Nagashima K, Koizumi H: Membrane expression of annexin I is enhanced by calcium and TPA in cultured human keratinocytes. Arch Dermatol Res. 2000 Oct;292(10):496-9.@@White MV, Igarashi Y, Lundgren JD, Shelhamer J, Kaliner M: Hydrocortisone inhibits rat basophilic leukemia cell mediator release induced by neutrophil-derived histamine releasing activity as well as by anti-IgE. J Immunol. 1991 Jul 15;147(2):667-73.@@Serres M, Viac J, Comera C, Schmitt D: Expression of annexin I in freshly isolated human epidermal cells and in cultured keratinocytes. Arch Dermatol Res. 1994;286(5):268-72. |
| Groups | Approved; Vet_approved |
| Direct Classification | 21-hydroxysteroids |
| SMILES | [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C |
| Pathways | Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency; Apparent Mineralocorticoid Excess Syndrome; Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH; 3-beta-Hydroxysteroid Dehydrogenase Deficiency; Corticosterone Methyl Oxidase I Deficiency (CMO I); Corticotropin Activation of Cortisol Production; 11-beta-Hydroxylase Deficiency (CYP11B1); Steroidogenesis; Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia Due to 17 alpha-Hydroxylase Deficiency; 17-alpha-Hydroxylase Deficiency (CYP17); Corticosterone Methyl Oxidase II Deficiency (CMO II); 21-Hydroxylase Deficiency (CYP21) |
| PharmGKB | PA449905 |
| ChEMBL | CHEMBL389621 |
